普乐可复在肾移植中的临床应用

目的 研究普乐可复（ＦＫ５０６）对肾移植患者免疫抑制的疗效与安全性。方法 肾移植术后应用ＦＫ５０６免疫抑制治疗８２例，分为临床验证组４２例和切换治疗组４０例。结果 临床验证组有４０例（９５．２％）肾功能在１４ｄ内恢复正常，１例（２．４％）发生急性排斥反应，经治疗逆转。切换治疗组有２４例肝功能正常；３例移植肾发生急性肾小管坏死（ＡＴＮ）伴急性排斥反应，６例发生慢性排斥反应，４例发生难治性排斥反应，均

Clinical Application of FK506 in renal transplantation

Objective To investigate the immunosuppressive effect and safety of FK506 for renal transplant recipients.Methods FK506 had been used as a postoperative immunosuppressant for 82 cases of renal transplantation. Among them, 42 cases were included in clinical checking group and 40 cases served as conversion groups. Results In the clinical checking group, renal function in 40 cases (95.2%) returned normal within 14 days. Acute rejection episode occurred in one case, but recovered after treatment (2.4%). In the conversion group, liver function of 24 cases gradually returned normal. ATN accompanied with acute rejection occurred in 3 cases, chronic rejection in 6 cases and knotty rejection in 4 cases. All of them were reversed after treatment. Two cases of severe gingival hyperplasia recovered completely and one case of abdomen pain subsided.Conclusions FK506 is a safe and effective immunosuppressant, and has a low incidence of rejection and less toxicity. It may be compared favorably with CsA. It might be a better measure for FK506 treating knotty and chronic rejection, severe liver function damage, gingival hyperplasia.